Tempus AI, Inc. (TEM) Earnings Call Transcripts

9 earnings calls from August 2024 to July 30, 2026

NASDAQ US Health Care Life Sciences Tools and Services

Tempus AI, Inc.'s Latest Earnings Call - Q1 FY2026

Tempus AI reported strong financial results for Q1 2026, with revenue reaching $348.1 million, a 36% increase year-over-year. The company's diagnostic revenue was $261.1 million, driven by oncology business growth. Data and applications revenue was $87 million, up 40.5% YoY. Tempus raised its full-year guidance to a range of $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million. This guidance increase, along with robust growth in both diagnostics and data businesses, could positively impact the stock.

Reported metrics

MetricValueContext
Revenue $348.1M (beat) vs $256M YoY, +36%
Diagnostic Revenue $261.1M (beat) +35% YoY
Data and Applications Revenue $87M (beat) +40.5% YoY
Adjusted EBITDA $65M (guidance) (beat) Increased from prior guidance
MRD Growth 500% (neutral) Limited by reimbursement

Guidance from management

Tempus raised its full-year revenue guidance to $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million, reflecting strong business performance.

What management said

I'll handle the adjusted EBITDA piece, and then Eric can address MRD. Much like the prior year, the progression should build as the months pass. In Q1 we saw roughly $13+ million of year-over-year improvement. Q2 should look much the same. Clearly, the second half carries more weight for data, and that drives wider margins and a greater amount falling through to the bottom line. As we noted early in the year, we're l...
— Jim Rogers, Q1 FY2026 earnings call
Dan, the sole point I'd tack on is this: nothing is being suggested about volumes just because we've got that reimbursement upside. Clearly, with reimbursement gains, nailing down precisely when they'll land is tough. As you know, our volume patterns remain really robust. Those two lines in the deck aren't hinting at anything.
— Jim Rogers, Q1 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns about the timing of FDA submissions and the impact of reimbursement on MRD growth. Questions also focused on the sustainability of data business growth and the visibility into achieving revenue targets.

Main topics on the call

Read the full Tempus AI, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Tempus AI, Inc.

Tempus AI, Inc. (TEM) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 9 calls on record spanning August 6, 2024 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.

Earnings Call History

EarningsCalls.dev has 9 Tempus AI, Inc. earnings call transcripts on record, spanning August 6, 2024 to July 30, 2026. Based on this history, Tempus AI, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the transcript.

Ticker
TEM
Exchange
NASDAQ
Country
US
Sector
Health Care
Industry
Life Sciences Tools and Services
Calls on record
9
First call
August 6, 2024
Most recent
July 30, 2026
Reporting cadence
quarterly
Quarter Date
Q2 FY2026 Jul 30, 2026 Read transcript →
Q1 FY2026 May 5, 2026 Read transcript →
Q4 FY2025 Feb 24, 2026 Read transcript →
Q3 FY2025 Nov 4, 2025 Read transcript →
Q2 FY2025 Aug 8, 2025 Read transcript →
Q1 FY2025 May 6, 2025 Read transcript →
Q4 FY2024 Feb 24, 2025 Read transcript →
Q3 FY2024 Nov 4, 2024 Read transcript →
Q2 FY2024 Aug 6, 2024 Read transcript →